Vanguard Group Inc Mustang Bio, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.32 - $8.27 $1,052 - $27,208	-3,290 Reduced 0.12%	2,663,669 $1.04 Million
Q3 2022 Nov 14, 2022	BUY	$0.46 - $7.2 $221,886 - $3.47 Million	482,361 Added 22.08%	2,666,959 $1.25 Million
Q2 2022 Aug 12, 2022	SELL	$0.58 - $1.13 $462,729 - $901,524	-797,809 Reduced 26.75%	2,184,598 $1.28 Million
Q1 2022 May 13, 2022	SELL	$0.73 - $1.81 $1.08 Million - $2.69 Million	-1,486,265 Reduced 33.26%	2,982,407 $3.01 Million
Q4 2021 Feb 14, 2022	SELL	$1.66 - $2.64 $70,719 - $112,469	-42,602 Reduced 0.94%	4,468,672 $7.42 Million
Q3 2021 Nov 12, 2021	BUY	$2.58 - $3.36 $65,312 - $85,058	25,315 Added 0.56%	4,511,274 $12.1 Million
Q2 2021 Aug 13, 2021	BUY	$2.7 - $3.81 $12.1 Million - $17.1 Million	4,485,959 New	4,485,959 $14.9 Million

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $27.4M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.